Skip to main content

Table 1 Currently open phase I/II clinical trials for lung cancer

From: Emerging therapeutic agents for lung cancer

Drug class

Drug

Mechanism of action

Clinical trials (phase)

Study design

Disease

Tumor epigenetics

Entinostat

Histone deacetylase (HDAC) inhibitor

NCT02437136 (1/2)

Combination

NSCLC

HBI-8000

NCT02718066 (1/2)

Combination

NSCLC

ACY 241

NCT02635061 (1)

Combination

NSCLC

Epacadostat

NCT02298153 (1)

Combination

NSCLC

Mocentinostat

NCT02805660 (1/2)

Combination

NSCLC

CC-486

DNA hypomethylation

NCT02250326 (2)

Combination

NSCLC

Azacitidine

NCT02009436 (1)

Monotherapy

NSCLC

RRX-001

DNA methylation, histone deacetylation, and lysine demethylation

NCT02489903 (2)

Monotherapy

NSCLC

Tumor metabolism

Ethaselen

Thioredoxin reductase

NCT02166242 (1)

Monotherapy

NSCLC

TAS-114

dUTPase

NCT02855125 (2)

Combination

NSCLC

ADI-PEG 20

Pegylated arginine deiminase

NCT02029690 (1)

Combination

NSCLC

CCT245737

Checkpoint kinase 1

NCT02797977 (1)

Combination

NSCLC/SCLC

LY2606368

NCT02860780 (1)

Combination

NSCLC/SCLC

CB-839

Glutaminase

NCT02771626 (1/2)

Combination

NSCLC

Immunotherapy

Cancer vaccines

CV301

Tumor peptide vaccine

NCT02840994 (1/2)

Combination

NSCLC

TG4010

NCT02823990 (2)

Combination

NSCLC

Gemogenovatucel-T

NCT02639234 (2)

Combination

NSCLC

CMB305

NCT02387125 (1)

Monotherapy

NSCLC

DC-CIK

Dendritic cell vaccine

NCT02688686 (1/2)

Monotherapy

NSCLC

DCVAC/LUCA

NCT02470468 (1/2)

Monotherapy

NSCLC

AGS-003-LNG

NCT02662634 (2)

Monotherapy

NSCLC

JNJ-64041757

Listeria vaccine

NCT02592967 (1)

Monotherapy

NSCLC

ADXS11-001

NCT02531854 (2)

Combination

NSCLC

DSP-7888

WT1 vaccine

NCT02498665 (1)

Monotherapy

NSCLC

S-588410

(HLA)-a*2402-restricted epitope peptides

NCT02410369 (2)

Monotherapy

NSCLC

AD-MAGEA3 and MG1-MAGEA3

MAGE-A3-expressing maraba virus

NCT02879760 (1/2)

Monotherapy

NSCLC

L-DOS47

Immunoconjugate

NCT02340208 (1/2)

Monotherapy

NSCLC

NCT02309892 (1)

Monotherapy

NSCLC

DRibbles

NCT01909752 (2)

Monotherapy

NSCLC

Checkpoint inhibitors

Enoblituzumab (MGA271)

B7-H3 antibody

NCT02475213 (1)

Combination

NSCLC

NCT01391143 (1)

Monotherapy

NSCLC

MGD009

NCT02628535 (1)

Monotherapy

NSCLC

CM-24

CEACAM1 antibody

NCT02346955 (1)

Combination

NSCLC

Indoximod

Indoleamine 2,3-dioxygenase (IDO) inhibitor

NCT02460367 (1/2)

Combination

NSCLC

AMG 820

Colony-stimulating factor 1 receptor (CSF1R)

NCT02713529 (1/2)

Combination

NSCLC

PF-05082566

4-1BB agonist

NCT02315066 (1)

Combination

NSCLC/SCLC

PBF-509

Adenosine A2a

NCT02403193 (1/2)

Combination

NSCLC

CPI-444

NCT02655822 (1)

Combination

NSCLC

PF-04518600

Anti-OX40 mAb

NCT02315066 (1)

Combination

NSCLC/SCLC

JNJ-61610588

Anti-VISTA

NCT02671955 (1)

Monotherapy

NSCLC/SCLC

PDR001

Anti-PD1

NCT02460224 (1/2)

Combination

NSCLC/SCLC

CA-170

Oral PDL1/PDL2/VISTA inhibitor

NCT02812875 (1)

Monotherapy

NSCLC/SCLC

Avelumab

PD- L1 inhibitor

NCT02584634 (2)

Combination

NSCLC

Varlilumab

Anti-CR27 mAb

NCT02335918 (1)

Combination

NSCLC

JNJ-64457107

Anti- CD40

NCT02829099 (1)

Monotherapy

NSCLC/SCLC

Modified T cell therapy

TIL

Tumor infiltrating lymphocytes

NCT02133196 (2)

Monotherapy

NSCLC

DC-CTL

Combined dendritic cells- cytotoxic t lymphocyte

NCT02766348 (2)

Monotherapy

NSCLC

NCT02886897 (1/2)

Combination

NSCLC

IMMUNICELL®

Autologous γδ- T lymphocytes

NCT02459067 (2/3)

Monotherapy

NSCLC

MAGE A10c796T

Chimeric antigen receptor T lymphocytes

NCT02592577 (1/2)

Monotherapy

NSCLC

NY-ESO-1c259T

NCT02588612 (1/2)

Monotherapy

NSCLC

ANTI-MUC1 CAR T

NCT02587689 (1/2)

Monotherapy

NSCLC

PD1 knockout cells

Modified T cell therapy

NCT02793856 (1)

Monotherapy

NSCLC

Targeted NK cells

Modified NK cell therapy

NCT02118415 (2)

Monotherapy

NSCLC

NCT02845856 (1/2)

Combination

NSCLC

WT1-TCRC4-T cells

WT1 targeted t cells

NCT02408016 (1/2)

Monotherapy

NSCLC

Cytokines

rSIFN-co

Recombinant interferon

NCT02387307 (1)

Monotherapy

NSCLC

ALT-803

IL- 15 agonist

NCT02523469 (1/2)

Combination

NSCLC

AM0010

Pegylated IL-10

NCT02009449 (1)

Monotherapy

NSCLC

AAT-007

Prostaglandin E receptor subtype 4

NCT02538432 (2)

Monotherapy

NSCLC

Poly-ICL

Toll-like receptor agonist

NCT02661100 (1/2)

Combination

NSCLC/SCLC

VTX-2337

NCT02650635 (1)

Monotherapy

NSCLC

L19-IL2

Antibody cytokine fusion protein

NCT02735850 (2)

Combination

NSCLC

CDX-1401

DEC-205/NY-eso-1 fusion protein

NCT02661100 (1/2)

Combination

NSCLC/SCLC

Targeted therapy

EGFR inhibitors

ABBV-221

EGFR

NCT02365662 (1)

Monotherapy

NSCLC

AC0010MA

EGFR T790M

NCT02448251 (1/2)

Monotherapy

NSCLC

Tesevatinib

EGFR (CNS penetrant)

NCT02616393 (2)

Monotherapy

NSCLC

JNJ-61186372

EGFR/MET bispecific mAb

NCT02609776 (1)

Monotherapy

NSCLC

AP32788

EGFR exon 20

NCT02716116 (1/2)

Monotherapy

NSCLC

MM-151 and MM-121

EGFR mAb

NCT02538627 (1)

Monotherapy

NSCLC

TargomiRs

EGFR ab bound mir-16

NCT02369198 (1)

Monotherapy

NSCLC

Multi-kinase inhibitors

Navitoclax

Bcl-2, Bcl-x, Bcl-w

NCT02520778 (1)

Combination

NSCLC

CT-707

ALK, FAK, Pyk2

NCT02695550 (1)

Monotherapy

NSCLC

Famitinib

c-Kit, VEGFR2, PDGFR, VEGFR3, FLT1, FLT3

NCT02356991 (2)

Monotherapy

NSCLC

NCT02364362 (1)

Combination

NSCLC

MGCD516

VEGFR, PDGFR, DDR2, TRK and Eph families

NCT02219711 (1)

Monotherapy

NSCLC/SCLC

Pexidartinib

Kit, FLT3, CAF1r

NCT02452424 (1/2)

Combination

NSCLC

Anlotinib

VEGF1/2/3, FGFR2

NCT02388919 (2/3)

Monotherapy

NSCLC

Entrectinib

NTRK1/2/3, ROS1, ALK

NCT02568267 (2)

Monotherapy

NSCLC

ASP2215

Axl, FLT3

NCT02495233 (1/2)

Combination

NSCLC/SCLC

PI3K/mTOR pathway inhibitors

MLN1117

PI3K

NCT02393209 (1/2)

Combination

NSCLC

AZD8186

NCT01884285 (1)

Monotherapy

NSCLC

LY3023414

PI3K, mTOR

NCT02443337 (2)

Combination

NSCLC

Other miscellaneous target inhibitors

LEE011

CDK 4/6

NCT02292550 (1/2)

Combination

NSCLC

Abemaciclib

NCT02308020 (2)

Monotherapy

NSCLC

NCT02779751 (2)

Monotherapy

NSCLC

NCT02079636 (1)

Combination

NSCLC

INK128

TORC1/2

NCT02503722 (1)

Combination

NSCLC

Alisertib

Aurora kinase inhibitor

NCT01471964 (1/2)

Combination

NSCLC

Ibrutinib

BTK

NCT02321540 (1/2)

Monotherapy

NSCLC

TAK-659

Syk

NCT02834247 (1)

Combination

NSCLC

Pyrotinib

HER2

NCT02535507 (2)

Monotherapy

NSCLC

EphB4-HSA

sEphB4

NCT02495896 (1)

Combination

NSCLC

Ficlatuzumab

Hepatocyte growth factor (HGF)

NCT02318368 (2)

Combination

NSCLC

AMG 479

IGFR-1

NCT01061788 (1)

Combination

NSCLC/SCLC

MM-121

HER3

NCT02387216 (2)

Combination

NSCLC

Defactinib

Focal adhesion kinase (FAK)

NCT02758587 (1/2)

Combination

NSCLC

JNJ-42756493

FGFR

NCT02699606 (2)

Monotherapy

NSCLC

INCB054828

NCT02393248 (1/2)

Monotherapy

NSCLC/SCLC

LOXO-101

NTRK1/2/3

NCT02576431 (2)

Monotherapy

NSCLC/SCLC

RXDX-101

NCT02097810 (1)

Monotherapy

NSCLC/SCLC

Rh-endostatin

NCT02375022 (2)

Combination

NSCLC

Cediranib

NCT02498613 (2)

Combination

NSCLC/SCLC

GSK3052230

FGF ligand trap

NCT01868022 (1)

Combination

NSCLC/SCLC

TRC105

Endoglin (CD105)

NCT02429843 (1)

Combination

NSCLC

MEK162

MEK

NCT01859026 (1)

Combination

NSCLC

PD-0325901

NCT02022982 (1/2)

Combination

NSCLC

Selumetinib

RAS/RAF/MEK/ERK

NCT01586624 (1)

Combination

NSCLC

Pacritnib

JAK2

NCT02342353 (1/2)

Monotherapy

NSCLC

AT13387

Heat shock protein 90

NCT02535338 (1/2)

Combination

NSCLC

AUY922

NCT01922583 (2)

Monotherapy

NSCLC

NCT01854034 (2)

Monotherapy

NSCLC

Galunisertib

TGFβ signaling

NCT02423343 (1/2)

Combination

NSCLC/SCLC

MSC2156119J

MET

NCT01982955 (1/2)

Combination

NSCLC

Ralimetinib

MAPK

NCT02860780 (1)

Combination

NSCLC/SCLC

LTT462

NCT02711345 (1)

Monotherapy

NSCLC

PF-06671008

P-cadherin

NCT02659631 (1)

Monotherapy

NSCLC/SCLC

BGB324

Axl

NCT02424617 (1/2)

Combination

NSCLC

DNA repair

VX790

ATR

NCT02487095 (1/2)

Combination

SCLC

Veliparib

PARP

NCT01386385 (1/2)

Combination

NSCLC

Olaparib

NCT02498613 (2)

Combination

NSCLC/SCLC

Chemotherapy

Plinabulin

Tubulin-depolymerization

NCT02846792 (1/2)

Combination

NSCLC

NCT02812667 (1)

Combination

NSCLC

PT-112

Platinum based

NCT02884479 (1/2)

Combination

NSCLC/SCLC

NC-6004

Micellar nanoparticle-encapsulated cisplatin

NCT02240238 (1/2)

Combination

NSCLC

EC1456

Folic acid-tubulysin conjugate

NCT01999738 (1)

Monotherapy

NSCLC/SCLC

Oncolytic virus

CVA21

Coxsackievirus A21

NCT02043665 (1)

Monotherapy

NSCLC

NCT02824965 (1)

Combination

NSCLC

  1. ALK anaplastic lymphoma kinase, ATR ataxia telangiectasia and Rad3-related protein, AXL AXL receptor tyrosine kinase, BTK Bruton’s tyrosine kinase, CDK 4/6 cyclin-dependent kinase 4/6, CEACAM1 carcinoembryonic antigen-related cell adhesion molecule 1, dUTPase deoxyuridine triphophatase, FAK focal adhesion kinase, FGF fibroblast growth factor, FLT1/3 fms-like tyrosine kinase 1/3, c-Kit proto-oncogene c-Kit, Her2 human epidermal growth factor receptor 2, HLA human leukocyte antigen, IGFR insulin-like growth factor receptor, JAK2 Janus kinase 2, MAGEA3 melanoma-associated antigen 3, MAPK mitogen-activated protein kinase, MEK mitogen-activated protein kinase kinase, mTOR mammalian target of rapamycin, NTRK3 neurotrophic tyrosine kinase, PARP poly ADP ribose polymerase, PDGFR platelet-derived growth factor receptor, PI3K phosphatidylinositide 3-kinases, sEphB4 soluble extracellular domain of EphB4, Syk spleen tyrosine kinase, VEGFR vascular endothelial growth factor receptor, VISTA V-domain Ig suppressor of T cell activation, WT1 Wilms’ tumor protein